Progressive Multifocal Leukoencephalopathy (PML) in 2 Patients Treated With Elranatamab
Oliver Tomkins(Guy's and St Thomas' NHS Foundation Trust), Dana Warcel(Guy's and St Thomas' NHS Foundation Trust), Hugues de Lavallade(King's College Hospital), Sam Douthwaite(Guy's and St Thomas' NHS Foundation Trust), Sajitha Sachchithanantham(The Royal Free Hospital), R. Maamari(Guy's and St Thomas' NHS Foundation Trust), Majid Kazmi, Amit Roy(Guy's and St Thomas' NHS Foundation Trust), Ella Gault(Guy's and St Thomas' NHS Foundation Trust), Tracy Dmello(Guy's and St Thomas' NHS Foundation Trust), Neeraj Kohli(Guy's and St Thomas' NHS Foundation Trust), Hamish Bain(Guy's and St Thomas' NHS Foundation Trust), Matthew Streetly(King's College - North Carolina)
Cited by 1
Related Papers
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
|The Lancet|2020|366
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315